Item 8.01 Other Events

In a press release issued on January 26, 2009, MAP Pharmaceuticals, Inc. (the "Company") announced that it has completed patient enrollment in the efficacy portion of a Phase 3 clinical trial of its MAP004 product candidate in patients with migraine. The Company noted that patient enrollment in the long-term safety arm of the trial is ongoing. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release of MAP Pharmaceuticals, Inc., dated January 26, 2009

---